Please login to the form below

Not currently logged in
Email:
Password:

Pradaxa

This page shows the latest Pradaxa news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new anticoagulant on the market with a reversal agent available.

Latest news

More from news
Approximately 22 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    At least the $225m will go some way towards paying for the $650m settlement of the US Pradaxa litigation Boehringer announced in May.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    So far in 2013 the company has seen continued growth of its next-generation anticoagulant Pradaxa against fierce competition from rival drugs from Bristol-Myers Squibb/Pfizer and Bayer; pledged to ... American College of Cardiology (ACC) to educate

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Dabigatran etexilate. Notwithstanding the initial setback for DTIs, Boehringer Ingelheim (BI) first launched its twice-daily DTI prodrug, dabigatran etexilate (Pradaxa/Pradax), in 2008.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics